EBC Highlights

KEYNOTE-522

SABCS 2021

Good data with further questions for future treatment…

Hope Hugo, MD

PALLAS

SABCS 2021

Negative results with hope for translational projects

Michael Untch, MD

cTRAK TN

SABCS 2021

Leading the way for other ct-DNA trials

Karen Gelmon, MD

BRE12-158

SABCS 2021

Molecular-guided treatment is of value in combination…

Andreas Schneeweiss, MD

Keynote-522

SABCS 2021

The next standard for TNBC?!

Rebecca Dent, MD

RXPonder; CCtGMA.32 (Metformin)

SABCS 2021

Solved and unsolved controversies of early breast…

Rebecca Dent, MD

RxPONDER

SABCS 2021

Benefit only related to chemotherapy?!

Giuseppe Curigliano, MD

CCtG MA.32 (Metformin)

SABCS 2021

Metformin shows no efficacy for most cancer patients

Karen Gelmon, MD

KEYRICHED-1

SABCS 2021

Hypothesis-generating study in the HER2-enriched…

Nadia Harbeck, MD

RXPONDER

SABCS 2021

Critical consideration of the study data is necessary

Nadia Harbeck, MD

Breast Pre-Cancer Atlas

SABCS 2021

Genomic signatures of DCIS

Alessandra Gennari, MD

CCtGMA.32 (Metformin)

SABCS 2021

Metformin is not an anti-cancer drug

Alessandra Gennari, MD

TEXT, SOFT

SABCS 2021

The risk-adapted decision for or against AI has to be…

Peter A. Fasching, MD

KeyNOTE-522

SABCS 2021

Re-evaluation confirms old data

Michael Untch, MD

EBC Highlights: Multi-Language

CCtGMA.32 (Metformin)

SABCS 2021

La metformina non può essere considerata un farmaco…

Alessandra Gennari, MD

KEYRICHED-1

SABCS 2021

Hypothesen-generierende Studie beim HER2-enriched…

Nadia Harbeck, MD

Bre12-158

SABCS 2021

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

Andreas Schneeweiss, MD

RxPONDER

SABCS 2021

E’ solo effetto della chemioterapia?

Giuseppe Curigliano, MD

RXPONDER

SABCS 2021

Kritische Betrachtung der Studiendaten notwendig

Nadia Harbeck, MD

TEXT, SOFT

SABCS 2021

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

Peter A. Fasching, MD

KeyNOTE-522

SABCS 2021

Erneute Auswertung bestätigt alte Daten

Michael Untch, MD

PALLAS

SABCS 2021

Negative Ergebnisse, aber Hoffnung für translationale…

Michael Untch, MD

Breast Pre-Cancer Atlas

SABCS 2021

"Signatures Genomiche " nel carcinoma duttale in situ

Alessandra Gennari, MD

EBC Discussions: SABCS 2021

Keynote-522; OlympiA

SABCS 2021

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

H. Rugo, K. Gelmon, S. Tolaney, N. Harbeck, A. Schneeweiss, M. Untch

RxPONDER

SABCS 2021

RxPONDER: Benefit only for pre-menopausal patients?…

N. Harbeck, K. Gelmon, S. Tolaney, H. Rugo, M. Untch, A. Schneeweiss

cTRAK TN

SABCS 2021

cTRAK TN: ctDNA monitoring not yet ready for primetime.…

S. Tolaney, K. Gelmon, N. Harbeck, H. Rugo, A. Schneeweiss, M. Untch

EBC Discussions: Treatment Perspectives

Destiny-Breast 03; DAISY; SUMMIT

SABCS 2021

HER2+ EBC: Chemotherapy free regimens? Extended…

G. Curigliano, A. Schneeweiss, R. Dent, P. A. Fasching, D. Lüftner

PALLAS; PENELOPE-B

SABCS 2021

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

P. A. Fasching, D. Lüftner, R. Dent, G. Curigliano, A. Schneeweiss

SABCS 2021

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

A. Schneeweiss, R. Dent, G. Curigliano, P. A. Fasching, D. Lüftner

Keynote-522

SABCS 2021

TNBC EBC: What is the new neoadjuvant standard…

R. Dent, A. Schneeweiss, G. Curigliano, P. A. Fasching, D. Lüftner

MBC Highlights

EMERALD

SABCS 2021

Oral SERDs for early setting and adjuvant therapy

Peter A. Fasching

Keynote-355; Tropion-PanTumor01

SABCS 2021

Exciting novel therapies for metastatic TNBC

Rebecca Dent, MD

Destiny-Breast03; DAISY

SABCS 2021

More good news for TDXd

Rebecca Dent, MD

EMERALD

SABCS 2021

Elacestrant - less than we expected

Elzbieta Senkus-Konefka, MD

TROPION-PanTumor01; ASCENT

SABCS 2021

TROP2 - new target for improved chemotherapy

Volkmar Müller, MD

Keynote-355

SABCS 2021

Final results of the CPS score subgroup analyses show…

Javier Cortes, MD

Tropion-PanTumor01

SABCS 2021

Promising results for TNBC patients

Barbara Pistilli, MD

EMERALD

SABCS 2021

Very good news for endocrine resistant metastatic…

Giuseppe Curigliano, MD

KeyNOTE-355

SABCS 2021

Effectiveness depending on PDL1 status

Michael Untch, MD

Pada-1

SABCS 2021

Switching with molecular progress improves PFS

Andreas Schneeweiss, MD

Nimbus; Keynote-355

SABCS 2021

Chekpoint inhibition in breast cancer

Volkmar Müller, MD

DAISY

SABCS 2021

Activity of T-Dxd across all Her2-expressing breast…

Sara Tolaney, MD

Keynote-522 Keynote-355 Destiny-Breast03

SABCS 2021

3 updates - 3 new standards of care

Karen Gelmon, MD

Tropion-PanTumor01

SBCS 2021

Dato-Dxd for metastatic TNBC

Sara Tolaney, MD

KeyNOTE-522

SABCS 2021

Robust benefit of pembroluzimab in addition to…

Véronique Diéras, MD

Nimbus

SABCS 2021

IO + IO without resounding success in the mBC setting

Diana Lüftner, MD

SABCS 2021

Amazing period for patients with refractory metastatic…

Carmen Criscitiello, MD

SABCS 2021

My highlights of 2021 in metastatic breast cancer

Javier Cortes, MD

Samuraciclib Phase I

SABCS 2021

Samuraciclib - new targeted therapy for luminal breast…

Elzbieta Senkus-Konefka, MD

SAFIR02-Breast

SABCS 2021

Pioneering study of personalized medicine in advanced…

Peter A. Fasching, MD

NIMBUS

SABCS 2021

Immuntherapy for high tumor mutation burden in…

Sara Tolaney, MD

Tropion-PanTumor01

SABCS 2021

Dato-DXd new promising ADC

Elzbieta Senkus-Konefka, MD

KEYNOT-355

SABCS 2021

Which patients will benefit from Pembro in metastatic…

Hope Rugo, MD

EMERALD

SABCS 2021

Oral SERDs are efficient, but show high progression…

Andreas Schneeweiss, MD

SAFIR02-Breast

SABCS 2021

Precision oncology is beneficial in certain mBC…

Andreas Schneeweiss, MD

Pada-1

SABCS 2021

PFS improvement with fulvestrant in patients with…

Véronique Diéras, MD

MONALEESA 2, 3, 7

SABCS 2021

Pooled analyses shows OS benefit for most subgroups

Peter A. Fasching, MD

SABCS 2021

Best of the year: systemic therapy

Andreas Schneeweiss, MD

Destiny-Breast03

SABCS 2021

T-Dxd is also active in patients with brain metastasis

Elzbieta Senkus-Konefka, MD

MSK IMPACT

SABCS 2021

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Peter A. Fasching, MD

Destiny-Breast03; DAISY

SABCS 2021

Reconfirming effect of T-DXd in patients with brain…

Véronique Diéras, MD

NeoTRIPaPDL1

ASH 2021

Imaging with mass cytometry can provide predictive…

Carmen Criscitiello, MD

DESTINY Breast-03

SABCS 2021

TDXd is very efficient in patients with brain…

Peter A. Fasching, MD

MBC Highlights: Multi-Language

Emerald

SABCS 2021

Buone notizie per i tumori mammari endocrino resistenti

Giuseppe Curigliano, MD

Destiny-Breast03

SABCS 2021

T-Dxd aktywny również w przerzutach do mózgu

Elzbieta Senkus-Konefka, MD

Keynote-522

SABCS 2021

Important benefice de l’ajout du pembrolizumab à la…

Véronique Diéras, MD

Samuraciclib Phase I

SABCS 2021

Samuracyklib – nowe leczenie celowane w rakach…

Elzbieta Senkus-Konefka, MD

Tropion-PanTumor01; Ascent

SABCS 2021

Neues Target für optimierte Chemotherapie

Volkmar Müller, MD

NeoTRIPaPDL1

SABCS 2021

L’imaging mass cytometry può aiutare a predire…

Carmen Criscitiello, MD

SAFIR02-BREAST

SABCS 2021

Präzisionsonkologie funktioniert beim mBC

Andreas Schneeweiss, MD

Pada-1

SABCS 2021

Amélioration de la survie sans progression par le…

Véronique Diéras, MD

SABCS 2021

Best of the Year: Systemtherapie

Andreas Schneeweiss, MD

Nimbus; Keynote-355

SABCS 2021

Checkpoint-Inhibition beim Mammakarzinom

Volkmar Müller, MD

Emerald

SABCS 2021

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Andreas Schneeweiss, MD

Nimbus

SABCS 2021

IO + IO ohne durchschlagenden Erfolg beim mBC

Diana Lüftner, MD

SABCS 2021

Mi retrospectiva del cáncer de mama metastático en 2021

Javier Cortes, MD

Tropion-PanTumor01

SABCS 2021

Résultats prometteurs dans le cancer du sein triple…

Barbara Pistilli, MD

Monaleesa 2, 3, 7

SABCS 2021

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Peter A. Fasching, MD

Emerald

SABCS 2021

Werden orale SERDs die Therapie mit Fulvestrant in…

Peter A. Fasching, MD

Destiny-Breast03

SABCS 2021

Activité du T-DXd dans les metastases cérébrales

Véronique Diéras, MD

PADA-1

SABCS 2021

Umstellung bei molekularem Progress verlängert PFS

Andreas Schneeweiss, MD

Tropion-PanTumor01

SABCS 2021

È un grande momento per i pazienti con tumore mammario…

Carmen Criscitiello, MD

Safir02-Breast

SABCS 2021

Wegweisende Daten für die personalisierte Medizin beim…

Peter A. Fasching, MD

Keynote-355

SABCS 2021

Resultados finales de los análisis de los subgrupos de…

Javier Cortes, MD

Tropion-PanTumor01

SABCS 2021

Risultati promettenti nel tumore al seno triplo…

Barbara Pistilli, MD

KeyNOTE-355

SABCS 2021

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Michael Untch, MD

Destiny-Breast-03

SABCS 2021

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Peter A. Fasching, MD

Tropion-PanTumor01

SABCS 2021

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

Elzbieta Senkus-Konefka, MD

MSK Impact

SABCS 2021

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Peter A. Fasching, MD

Emerald

SABCS 2021

Elacestrant – poniżej oczekiwań

Elzbieta Senkus-Konefka, MD

MBC Discussions: Treatment Perspectives

SABCS 2021

MBC HER2+: How can we manage the metastatic disease and…

J. Cortes, D. Lüftner, C. Criscitiello, V. Dieras, F. Cardos, V. Müller

SABCS 2021

MBC TNBC: Molecular tumor characteristics define the…

V. Dieras, D. Lüftner, C. Criscitiello, F. Cardoso, J. Cortes, V. Müller

SABCS 2021

MBC HR+: What is the best option after a CDK4/6i…

C. Criscitiello, V. Müller, V. Dieras, J. Cortes, F. Cardoso, D. Lüftner

SABCS 2021

Integrating patients perspectives in metastatic breast…

Cardoso, V. Müller, C. Criscitiello, V. Dieras, J. Cortes, D. Lüftner

MBC Discussions: SABCS 2021

SUMMIT

SABCS 2021

Targeting rare mutations in breast cancer - is this the…

V. Müller, A. Gennari, B. Pistilli, E. Senkus-Konefka, M. Untch

TROPION-Tumor01

SABCS 2021

New ADCs on the horizon for TNBC patients

M. Untch, B. Pistilli, E. Senkus-Konefka, A. Gennari, V. Müller

Destiny-Breast03

SABCS 2021

Therapy of brain metastasis – can T-DXd be the new SoC?

M. Untch, E. Senkus-Konefka, A. Gennari, B. Pistilli, V. Müller

EMERALD

SABCS 2021

Are SERDs a future therapy for endocrine resistant…

M. Untch, V. Müller, B. Pistilli, A. Gennari, E. Senkus-Konefka

Keynote-355

SABCS 2021

Treatment options for patients with metastatic TNBC

V. Müller, A. Gennari, B. Pistilli, E. Senkus-Konefka, M. Untch